- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA targets unapproved oxycodone products
FDA is ridding the market of single-ingredient oxycodone capsules that are being distributed without an FDA-approved application.
FDA is ridding the market of single-ingredient oxycodone capsules and oral liquids that are being distributed without an FDA-approved application.
“Action will be taken against companies that manufacture the unapproved oxycodone products on or after August 20, 2012, or that ship unapproved products on or after October 4, 2012,” according to a statement from the American Society of Health-Systems Pharmacists about the FDA action.
FDA is targeting select single-ingredient, immediate-release oxycodone hydrochloride capsules and oral liquids that do not have an FDA-approved application, such as: 5 mg and 20 mg/mL oral solution by Lannett Company; 5 mg capsules, 1 mg/mL oral solution, and 20 mg/mL oral solution by Mallinckrodt; and 5 mg capsules by Physicians Total Care.
The agency is concerned about the products’ labeling. For example, the labeling for the unapproved 20 mg/mL oral solution does not state that the oxycodone concentrate is for use only by opioid-tolerant patients.
Pharmaceutical Compounding, Storage of Faricimab Preserves Stability, Binding Properties
November 28th 2023Maintaining the structure and function of antibody biologics like faricimab is critical for their administration via intravitreal injection (IVI), a common treatment approach for retinal diseases.
